liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
St Olavs Hospital, Norway; Norwegian University of Science and Technology NTNU, Norway.
Karolinska University Hospital, Sweden; Karolinska Institute, Sweden.
University of Uppsala Hospital, Sweden.
Linköping University, Department of Medical and Health Sciences. Region Östergötland, Center for Surgery, Orthopaedics and Cancer Treatment, Department of Haematology. Linköping University, Faculty of Medicine and Health Sciences.
Show others and affiliations
2015 (English)In: European Journal of Haematology, ISSN 0902-4441, E-ISSN 1600-0609, Vol. 94, no 3, 243-250 p.Article in journal (Refereed) Published
Abstract [en]

We randomised 46 newly diagnosed patients with chronic myeloid leukaemia (median age 56) to receive dasatinib 100mg QD or imatinib 400mg QD and report outcome as an intention-to-treat analysis with 36months follow-up. Early cytogenetic and molecular responses were superior in the dasatinib group, with a tendency that imatinib patients caught up with time. For instance, MR3.0 was reached at 3months in 36% vs. 8% (P=0.02), at 12months in 81% vs. 46% (P=0.02) and at 18months in 73% vs. 65% (n.s.) of the patients in the two groups. In contrast, MR4.5 was consistently superior in the dasatinib group at all time points from 6months onwards, reaching 61% vs. 21% (Pless than0.05) at 36months. Sixty-four vs. 71% of the patients in the dasatinib and imatinib arms, respectively, remained on assigned drug. Dasatinib dose was frequently reduced, but with maintained excellent effect. One imatinib patient progressed to blastic phase, but no CML-related deaths occurred. In conclusion, our data compare favourably with those of the dasatinib registration study, DASISION. The fast and deep molecular responses induced by dasatinib compared with imatinib may be exploited to increase the proportion of patients who can achieve a treatment-free remission after treatment discontinuation.

Place, publisher, year, edition, pages
Wiley: 12 months , 2015. Vol. 94, no 3, 243-250 p.
Keyword [en]
dasatinib; imatinib; randomized controlled trial; deep response; toxicity
National Category
Clinical Medicine
URN: urn:nbn:se:liu:diva-116957DOI: 10.1111/ejh.12423ISI: 000350357900008PubMedID: 25082346OAI: diva2:802098

Funding Agencies|Bristol-Myers Squibb

Available from: 2015-04-10 Created: 2015-04-10 Last updated: 2016-04-24

Open Access in DiVA

fulltext(647 kB)134 downloads
File information
File name FULLTEXT01.pdfFile size 647 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Dreimane, ArtaLotfi, Kourosh
By organisation
Department of Medical and Health SciencesDepartment of HaematologyFaculty of Medicine and Health SciencesDivision of Drug ResearchFaculty of Health SciencesDepartment of Clinical Pharmacology
In the same journal
European Journal of Haematology
Clinical Medicine

Search outside of DiVA

GoogleGoogle Scholar
Total: 134 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 89 hits
ReferencesLink to record
Permanent link

Direct link